Tyler C. Liu is an associate in Sterne Kessler’s Biotechnology & Chemical Practice Group. He has experience in the preparation and filing of petitions for inter partes review (IPR) under the America Invents Act and has been involved in several IPR proceedings representing both patent owners and petitioners. He has also been involved in pharmaceutical patent litigations brought under the Hatch-Waxman Act.

Before joining Sterne Kessler, Tyler was in-house counsel at a generic pharmaceutical company, where he assisted in providing strategic planning regarding IPR matters and drafted IPR petitions, expert declarations, and other papers for several IPR proceedings.

During graduate school, Tyler studied missense polymorphisms in the gene encoding gonadotropin-releasing hormone among patients with metastatic prostate cancer at the National Cancer Institute of the National Institutes of Health. Tyler received his J.D. from The George Washington University Law School, his M.S. in biochemistry and molecular biology from Georgetown University, and his B.A. in molecular and cellular biology from the University of California, Berkeley.


  • J.D., The George Washington University Law School
  • M.S., Biochemistry and Molecular Biology, Georgetown University, Academic Excellence Award
  • B.A., Molecular and Cellular Biology, Neurobiology, minor in Chinese, University of California at Berkeley


  • District of Columbia
  • Texas
  • United States Patent & Trademark Office

Languages Spoken

  • Chinese (Mandarin)

Related News & Insights From Tyler C. Liu

In the News DNA Sequencing Patent Survives Guardant PTAB Challenge Law360 October 11, 2023
In the News Almirall Loses Appeal on Acne Treatment Patent at Fed. Cir. Bloomberg Law March 14, 2022
In the News Fed. Circ. Affirms PTAB's Ax of Acne Drug Patent Law360 March 14, 2022
Press Release Sterne Kessler Publishes 2021 PTAB Year in Review: Analysis & Trends Report Sterne, Kessler, Goldstein & Fox March 7, 2022
Press Release Sterne Kessler Client Wins 2020 Nobel Prize in Chemistry for CRISPR-Cas9 Technology Sterne, Kessler, Goldstein & Fox P.L.L.C. October 8, 2020